Unlocking the health benefits of cannabinoids.

Today, the official cornerstone paper of the German government on the controlled dispensing of cannabis to adults for consumption purposes was presented. This follows details released from an internal, non-coordinated draft that became public last week. From the point of view of Sanity Group, one of the leading cannabis companies in Germany, the final and revised version contains interesting approaches and some fruitful frameworks, but the Berlin-based company is critical of certain points.

Leading German cannabis company Sanity Group announced today a $37.6M Series B financing round – Europe’s largest cannabis investment round to date. The funding round was led by BAT Group* with ongoing commitment from existing Sanity Group investors such as Redalpine and Casa Verde Capital and brings total funds raised by the company to over $100M.

Berlin-based Sanity Group has signed new, exclusive supply agreements for medical cannabis with partners from Portugal, South Africa and Canada, securing further exclusive rights to around 20 high-THC cannabis flos from selected cultivars with a minimum volume of three tons per year for the brands Vayamed and AVAAY Medical. Deliveries are already scheduled to start at the end of the third quarter and beginning of the fourth quarter of 2022. In addition, further important strategic partnerships have been signed.